[Pangyo Bio & Medical] Speclipse selected as one of the ‘Top 10 Medical Devices’ companies by U.S. Medtech Outlook

Speclipse (CEO Byun Seong-hyun) announced on the 15th that it was selected as one of the 2021 ‘Top 10 Non Invasive Device Companies’ announced by the U.S. MedTech Outlook. Speclips is a company specializing in medical diagnosis based on laser spectroscopy technology and artificial intelligence (AI).

MedTech Outlook is America’s authoritative healthcare media. Every year, among global non-implantable medical device companies, 10 companies that have shown innovative results by utilizing big data and the Internet of Things (IoT) are selected. Among the top 10 companies selected in 2021, Speclipse is the only Asian company. In addition, Boston Scientific, a famous global medical device company, and Alma Laser, Israel, were included.

Speclips received high scores for the technology and innovation of Spectra-Scope, a skin cancer diagnostic device developed by MedTech Outlook. Spectra-Scope diagnoses suspected skin cancer areas in real time and non-invasively. It is evaluated that it can identify skin cancer with a private test score of 95% and a specificity of 87%, thereby reducing unnecessary biopsies and increasing convenience for patients, thereby increasing diagnostic accuracy and efficiency.

MedTech Outlook analyzed, “It is innovative that Speclipse is attempting early diagnosis of stomach cancer, Alzheimer’s, and pancreatic cancer using blood by expanding the scope of application of laser spectroscopy and AI technology.” Accordingly, Speclipse was featured on the cover of the September issue of MedTech Outlook, and a special interview was published.

Seonghyun Byun, CEO of Speclipse, said, “Being named as one of the top 10 companies selected by Medtech Outlook is an important achievement that directly recognizes overseas the technology and marketability of Spectra-Scope, a skin cancer diagnosis device that can be applied in real time non-invasively.” said.

Speclips, which started as a cancer diagnostic device developer, was founded in 2015 by graduates of Stanford University with master’s and doctoral degrees. The first product, Spectra-Scope, a skin cancer diagnostic device, obtained overseas medical device certification in Australia, Europe, and Brazil in 2020, and is building a sales network in over 20 countries around the world. Recently, Spectra-Scope was approved in Australia and Europe. We are expanding our sales channels, focusing on Western countries with a high prevalence of skin cancer.

Meanwhile, Speclips selected Korea Investment & Securities as the underwriter for the initial public offering (IPO) in September this year and began preparations for listing on the KOSDAQ in 2022. The goal is to submit a preliminary review request in the second half of 2022. Speclips plans to expand its overseas business by raising funds in the public offering market and accelerate its growth by conducting clinical trials on blood analysis devices.

Source:  Pangyo Techno Valley Official Newsroom

→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news